Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma

Background Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancers have emerged as key predictive biomarkers in EGFR tyrosine kinase inhibitor (TKI) treatment. However, a few patients with wild-type EGFR also respond to EGFR TKIs. This study investigated the factors predict...

Full description

Bibliographic Details
Main Authors: Seo Yun Kim, M.D., Jae Kyung Myung, M.D., Hye-Ryoun Kim, M.D., Im Il Na, M.D., Ph.D., Jae Soo Koh, M.D., Ph.D., Hee Jong Baek, M.D., Ph.D., Cheol Hyeon Kim, M.D., Ph.D.
Format: Article
Language:English
Published: The Korean Academy of Tuberculosis and Respiratory Diseases 2019-01-01
Series:Tuberculosis and Respiratory Diseases
Subjects:
adenocarcinoma
receptor
epidermal growth factor
lung neoplasms
Online Access:https://www.e-trd.org/search.php?where=aview&id=10.4046/trd.2018.0004&code=0003TRD&vmode=FULL

Internet

https://www.e-trd.org/search.php?where=aview&id=10.4046/trd.2018.0004&code=0003TRD&vmode=FULL

Similar Items